December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

141.82 -0.75 (-0.53%)
Delayed Quote Updated: 12:04 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
59 60 Next >
News headline image
Is NYSE:NVS a Good Fit for Dividend Investing? ↗
Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing? 
Via Chartmill
News headline image
The 3 Most Undervalued Pharma Stocks to Buy in July 2024 ↗
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued. 
Via InvestorPlace
Topics Economy
News headline image
Novartis Stock Generating Improved Relative Strength ↗
Top and bottom line growth moved higher in Novartis' most recent quarter. EPS rose 17% to $1.80. Revenue increased 10% to $12.1 billion. 
Via Investor's Business Daily
News headline image
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures ↗
UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches in financial categorization and highlights similar issues with Novartis... 
Via Benzinga
News headline image
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
News headline image
Exploring NYSE:NVS's dividend characteristics. ↗
Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) qualifies as a good dividend investing stock. 
Via Chartmill
News headline image
Balancing Dividends and Fundamentals: The Case of NYSE:NVS. ↗
Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing? 
Via Chartmill
News headline image
Upcoming Stock Spinoffs: Should You Pounce or Pass? ↗
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
News headline image
Mississippi Judge Upholds State Law Mandating Drug Discounts for Low-Income Patients ↗
A Mississippi judge upheld a state law requiring drugmakers to offer discounts on medications through third-party pharmacies for low-income populations, rejecting lawsuits from PhRMA and Novartis. 
Via Benzinga
Topics Lawsuit
News headline image
Superlab Suisse opens state-of-the-art facility in Basel, fostering new spaces for scientific breakthroughs
With this new facility, Superlab Suisse becomes the largest private lab space in Switzerland. 
Via News Direct
News headline image
Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade ↗
Novartis stock is in a buy range after moving past a 103.55 entry in a cup with handle. The buy range extends to 5% above the initial entry. 
Via Investor's Business Daily
News headline image
Nestle Carefully Targets Weight-Loss Drug Users with New Food Line ↗
Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addressing regulatory concerns and focusing on marketing through social media. 
Via Benzinga
News headline image
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount ↗
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
News headline image
What's Going On With Neurological Disease Focused Trevena On Thursday? ↗
Trevena shares dropped 33.7% to $0.23 with a session volume of 23.65 million. Notably, TRV045 did not cause S1P1R desensitization or protein reduction, unlike fingolimod. 
Via Benzinga
News headline image
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
News headline image
3 Crazy Good Stocks to Buy With $500 Right Now ↗
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. 
Via InvestorPlace
News headline image
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations ↗
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis. 
Via Benzinga
Leigh Burgess, CEO & Founder Bold Industries Group, Announces Pre-Sale of New Book: Be BOLD Today
Via Get News
News headline image
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024 ↗
Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks. 
Via InvestorPlace
News headline image
Novartis Sues to Block Maryland's New Drug Discount Law ↗
Novartis has filed a lawsuit to block a Maryland law requiring drugmakers to offer discounts on drugs through third-party pharmacies contracting with hospitals and clinics. 
Via Benzinga
Topics Lawsuit
News headline image
Novartis' Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety ↗
Novartis reveals Phase 3 data confirming remibrutinib's long-term efficacy and safety for chronic spontaneous urticaria, showing significant symptom improvement and a favorable safety profile up to... 
Via Benzinga
News headline image
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February ↗
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
News headline image
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game ↗
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
News headline image
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs ↗
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade ↗
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
News headline image
3 Magnificent Stocks That Are Passive Income Machines ↗
These three companies have track records that should please investors. 
Via The Motley Fool
News headline image
The 3 Best Mutual Funds to Buy in May 2024 ↗
Consider the best mutual funds to buy for high returns and low fees. They each have unique strategies meant to maximize returns on capital. 
Via InvestorPlace
News headline image
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths' ↗
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets. 
Via Benzinga
News headline image
3 Biotech Stocks to Sell in May Before They Crash & Burn ↗
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio. 
Via InvestorPlace
News headline image
Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease ↗
Google DeepMind reveals its AlphaFold 3, which specializes in molecular predictions for proteins, DNA, RNA, and drug molecules. 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.